In 2023, 4,514 clinical cases were reported across 36 states and Washington, D.C. Clinical cases refer to those in which infection is present, whereas screening cases refer to those where fungus is detected and has colonized, but has not led to infection.
This is a significant jump from 2022, when 2,928 clinical cases were reported. C. auris is considered an urgent public health threat due to its resistance to multiple antifungal treatments and ability to spread quickly in healthcare settings, particularly among immunocompromised people.
Below is a list of the number of clinical cases reported in the U.S. in 2023, per the CDC:
California: 642
Nevada: 599
Florida: 568
Texas: 492
Illinois: 477
New York: 413
Georgia: 192
Ohio: 161
Arizona: 124
Michigan: 114
Indiana: 113
Tennessee: 99
Maryland: 97
Virginia: 81
New Jersey: 75
Pennsylvania: 39
Mississippi: 35
Louisiana: 28
Delaware: 25
District of Columbia: 23
Kentucky: 19
North Carolina: 18
Alabama: 13
Wisconsin: 11
Arkansas: 9
Oklahoma: 8
South Carolina: 7
Massachusetts: 6
Iowa: 5
Minnesota: 5
Connecticut: 4
West Virginia: 4
Colorado: 2
Missouri: 2
Oregon: 2
Nebraska: 1
Utah: 1
